Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Personalised medicine: how the 2011 Multidisciplinary Cancer Congress will mark important milestones in getting the right treatment to the right patient at the right time (2/5)

EMCC 2011

23 - 27 Sep 2011

Published: 11 Apr 2011

Views: 5214

Rating:

Save

Michael Baumann - ECCO President & Congress Chair; David Kerr - ESMO President; Anne-Lise Børresen Dale - Scientific Co-Chair (ECCO)

Underpinning the role, relevance and importance of each and every specialty in oncology at the meeing discussants describe the power of multidisciplinarity in advancing cancer research, treatment and care. By anticipating just some of the groundbreaking basic, translational and clinical data they expect to see presented and intermingled in Stockholm, the panel highlights the multidisciplinary and multi-professional scope, appeal and draw of the Congress.

Related Videos

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

EMUC 2024: Optimising strategies in mHSPC and mCRPC

Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz

EMUC 2024: Optimising strategies in mHSPC and mCRPC ( Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz )

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA

Dr Bruna Pellini - Moffitt Cancer Center, Tampa, USA

Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA ( Dr Bruna Pellini - Moffitt Cancer Center, Tampa, USA )

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

War in Ukraine: The logistical challenges of transferring medical materials

Dr Horia Vulpe, Dr Ruslan Baltaga

War in Ukraine: The logistical challenges of transferring medical materials ( Dr Horia Vulpe, Dr Ruslan Baltaga )

Navigating evidence-based care with limited resources in Africa

Dr Verna Vanderpuye - National center for Radiotherapy and Nuclear Medicine, Accra, Ghana

Navigating evidence-based care with limited resources in Africa ( Dr Verna Vanderpuye - National center for Radiotherapy and Nuclear Medicine, Accra, Ghana )

More from ecancer